Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Richard Price

Professor Richard Price

Podcast interview

Curing Plasmodium vivax malaria

Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.

View podcast transcript

Ethiopian Clinic

Recruitment site for the multicentred IMPROV trial in Ethiopia

Vietnam Hospital

Vietnam Clinic recruiting site for the IMPROV study

Social media

Richard Price

Professor of Tropical Medicine

Vivax malaria

The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with in malaria endemic countries across the Asia-Pacific region and Horn of Africa to:

  • optimise the safe and effective radical cure of vivax malaria,
  • improve the molecular surveillance of drug resistant malaria
  • define the morbidity and mortality of vivax malaria
  • evaluate the impact and cost effectiveness of novel treatment and malaria control activities.

The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.

I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN). Between 2010-2020 he established co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).


  • Clinical trials and implementation studies of different primaquine regimens
  • Field testing novel G6PD diagnostics
  • Mapping populations at risk of malaria and drug induced haemolysis
  • Determining the molecular basis of chloroquine resistant P. vivax
  • Individual patient data metanalyses of antimalarial efficacy studies

Timika, Papua, Indonesia

Main hospital in southern Papua, where over the last 10 years we have been defining the epidemiology of severe and uncomplicated malaria

RSMM Hospital

Outpatient clinic in Papua Indonesia

Sumatra Site for IMPROV Study

South Sumatra Site for IMPROV in Indonesia

Ex vivo Lab

Testing novel antimalarial drug in field assays